News Release


Results of Overseas Clinical Studies for KRP-104, anti-diabetes agent

August 20, 2008

Kyorin Pharmaceutical Co., Ltd (Tokyo, President: Mr. Itaru Kojo), a subsidiary of Kyorin Co., Ltd. announced that the target goals of major endpoints of overseas Ph1b (in US) and Ph2a (in US and India) clinical studies for KRP-104 were achieved. KRP-104 is a DPP-4 inhibitor originated by Kyorin Pharmaceutical and jointly filed IND to US FDA by Kyorin and ActivX Bioscience, Inc. (California, USA, Chairman, President: Dr. John W. Kozarich), a wholly owned subsidiary of Kyorin Pharmaceutical.

Get Adobe Acrobat Reader

Adobe Reader software is required to view and print PDF files. The latest version of Adobe Reader can be downloaded by accessing the Adobe Systems Incorporated website.